Security
Corbus Pharmaceuticals Holdings, Inc. Common Stock · CRBP
CRBPNASDAQCommon stockCurrentCIK 1595097Updated Oct 4, 2026
Name history
SAV Acquisition Corp · through Jan 10, 2014
CRBP price & chart
Loading TradingView…
NASDAQ:CRBP on TradingView ↗About the company
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
In the news
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer ↗
Seeking Alpha
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - Slideshow ↗
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript ↗
Corbus gets green light to begin pivotal trial of ADC for oropharyngeal cancer ↗
Recent filings
SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding Corbus Pharmaceuticals Holdings, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
4 filing
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 168,195,000Source | 155,879,000Source | 28,272,393Source | 66,311,940Source |
| Property, Plant and Equipment, NetUSD | 159,000Source | 385,000Source | 973,214Source | 1,613,815Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 28,492,000Source | 17,198,000Source | 13,723,681Source | 17,002,715Source |
| Assets, CurrentUSD | 166,954,000Source | 152,976,000Source | 23,546,030Source | 60,181,102Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,015,000Source | 3,629,000Source | 2,447,549Source | 791,616Source |
| Operating Lease, Right-of-Use AssetUSD | 1,082,000Source | 2,133,000Source | 3,062,920Source | 3,884,252Source |
| Other Assets, NoncurrentUSD | — | 0Source | 212,804Source | 155,346Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 20,692,000Source | 13,451,000Source | 35,177,115Source | 33,321,923Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 1,000Source | 442Source | 417Source |
| Additional Paid in CapitalUSD | 702,984,000Source | 619,285,000Source | 429,780,375Source | 425,196,359Source |
| Retained Earnings (Accumulated Deficit)USD | -555,430,000Source | -476,893,000Source | -436,683,983Source | -392,080,667Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -53,000Source | 35,000Source | -1,556Source | -126,092Source |
| Stockholders' Equity Attributable to ParentUSD | 147,503,000Source | 142,428,000Source | -6,904,722Source | 32,990,017Source |
| Liabilities and EquityUSD | 168,195,000Source | 155,879,000Source | 28,272,393Source | 66,311,940Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 20,692,000Source | 11,818,000Source | 31,894,073Source | 12,639,938Source |
| Operating Lease, Liability, CurrentUSD | 1,633,000Source | 1,606,000Source | 1,436,723Source | 1,280,863Source |
| Accounts Payable, CurrentUSD | 2,215,000Source | 4,786,000Source | 3,178,516Source | 2,173,963Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 1,633,000Source | 3,238,631Source | 4,675,354Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 44,411Source | 22,205Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 16,844,000Source | 5,426,000Source | 11,030,506Source | 5,999,252Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | — | — | 15,908,214Source | 2,795,669Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 0Source | 15,984,426Source |
| Short-term InvestmentsUSD | 134,777,000Source | 131,864,000Source | 7,182,325Source | 42,194,296Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -78,537,000Source | -40,209,000Source | -44,603,316Source | -42,346,903Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,288,000Source | 6,145,000Source | 3,470,154Source | 5,719,637Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -2,349,000Source | 1,603,000Source | 1,028,283Source | -256,835Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -64,491,000Source | -41,794,000Source | -36,100,473Source | -37,544,435Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,641,000Source | -121,310,000Source | 35,641,961Source | 30,074,133Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,000Source | — | 0Source | 13,449Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 77,426,000Source | 166,578,000Source | -2,820,522Source | -533,615Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,294,000Source | 3,474,000Source | -3,279,034Source | -8,003,917Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 29,162,000Source | 17,868,000Source | 14,393,581Source | 17,672,615Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 2,818,000Source | 2,607,474Source | 1,969,583Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,288,000Source | 6,145,000Source | 3,470,154Source | 5,719,637Source |
| DepreciationUSD | 200,000Source | 600,000Source | 641,000Source | 763,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 11,101Source | -427,436Source |
| Gain (Loss) on Sale of DerivativesUSD | — | — | -2,582Source | 96,842Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -21,235Source |
| General and Administrative ExpenseUSD | 15,215,000Source | 16,499,000Source | 13,909,641Source | 18,698,619Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 0Source | 1,872,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | -88,000Source | 36,000Source | 124,536Source | -63,647Source |
| Net Income (Loss) Attributable to ParentUSD | -78,537,000Source | -40,209,000Source | -44,603,316Source | -42,346,903Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -78,537,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 6,773,000Source | 8,512,000Source | 473,985Source | -2,511,458Source |
| Operating ExpensesUSD | 85,310,000Source | 48,721,000Source | 45,077,301Source | 39,835,445Source |
| Operating Lease, ExpenseUSD | — | — | 1,700,005Source | 1,652,563Source |
| Other Nonoperating Income (Expense)USD | 1,243,000Source | 4,073,000Source | 3,389,440Source | -48,773Source |
| Payments to Acquire InvestmentsUSD | 163,091,000Source | 180,804,000Source | 33,884,689Source | 86,341,894Source |
| Proceeds from Issuance of Common StockUSD | 77,426,000Source | 182,058,000Source | 244,302Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 1,381,729Source |
| Proceeds from Issuance of Redeemable Preferred StockUSD | — | — | — | 100Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -85,310,000Source | -48,721,000Source | -45,077,301Source | -39,835,445Source |
| Other Nonoperating Income (Expense)USD | 1,243,000Source | 4,073,000Source | 3,389,440Source | -48,773Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -78,537,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -78,537,000Source | -40,209,000Source | -44,603,316Source | -42,346,903Source |
| Earnings Per Share, BasicUSD per share | -5.9Source | -3.68Source | -10.31Source | -10.15Source |
| Earnings Per Share, DilutedUSD per share | -5.9Source | -3.68Source | -10.31Source | -10.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 13,317,116Source | 10,915,413Source | 4,327,568Source | 4,170,675Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 13,317,116Source | 10,915,413Source | 4,327,568Source | 4,170,675Source |
| Interest Expense (non-operating)USD | 0Source | 1,872,000Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 233,000Source | 588,000Source | 640,601Source | 762,995Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 11,101Source | -427,436Source |
| General and Administrative ExpenseUSD | 15,215,000Source | 16,499,000Source | 13,909,641Source | 18,698,619Source |
| Interest Expense, DebtUSD | 0Source | 1,800,000Source | 3,810,000Source | 3,097,000Source |
| Interest Income (Expense), NetUSD | — | — | -2,923,974Source | -2,132,091Source |
| Net Investment IncomeUSD | 5,530,000Source | 6,311,000Source | — | — |
| Nonoperating Income (Expense)USD | 6,773,000Source | 8,512,000Source | 473,985Source | -2,511,458Source |
| Operating ExpensesUSD | 85,310,000Source | 48,721,000Source | 45,077,301Source | 39,835,445Source |
| Operating Lease, ExpenseUSD | — | — | 1,700,005Source | 1,652,563Source |
| Other IncomeUSD | 229,000Source | -189,000Source | — | — |
| Research and Development ExpenseUSD | 70,095,000Source | 32,222,000Source | 31,167,660Source | 16,136,826Source |
Offerings
Registration 333-294217
Filing attachments
crbp-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 2 crbp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed • CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile • Data sup…
Read attachment ↗crbp-ex99_2.htm · 8-K · 2026-09-14
EX-99.2 3 crbp-ex99_2.htm EX-99.2 Connecting Innovation to Purpose Corporate Presentation September 14, 2026 Exhibit 99.2 This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including ti…
Read attachment ↗crbp-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 crbp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026 • Appointed new Chief Medical Officer, Chief B…
Read attachment ↗crbp-ex99_1.htm · 8-K · 2026-07-06
EX-99.1 3 crbp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer Norwood, MA, July 6, 2026 (GLOBE NEWSWIRE) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. “We’re thrilled to welcome Dr. Nicacio …
Read attachment ↗crbp-ex4_1.htm · S-8 · 2026-06-17
Exhibit 4.1 CORBUS PHARMACEUTICALS HOLDINGS, INC. 2026 INDUCEMENT AWARD PLAN 1. Establishment and Purpose 1.1 The purpose of the Corbus Pharmaceuticals Holdings, Inc. 2026 Inducement Award Plan (the “Plan”) is to attract personnel for positions with Corbus Pharmaceuticals Holdings, Inc. (the “Company”) and its Subsidiaries through grants of Awards under the Plan which induce them to join the Company or its Subsidiaries. It is anticipated that providing such persons with a direct stake in th…
Read attachment ↗crbp-ex4_2.htm · S-8 · 2026-06-17
Exhibit 4.2 NONQUALIFIED STOCK OPTION INDUCEMENT GRANT AGREEMENT CORBUS PHARMACEUTICALS HOLDINGS, INC. This Stock Option Inducement Grant Agreement (this “Agreement” or “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”). WHEREAS, the Company desires to provide the Option…
Read attachment ↗